Computational prediction and identification of HLA-A2.1-specific Ebola virus CTL epitopes  by Sundar, Krishnan et al.
7) 257–263
www.elsevier.com/locate/yviroVirology 360 (200Computational prediction and identification of HLA-A2.1-specific
Ebola virus CTL epitopes
Krishnan Sundar 1, Agnieszka Boesen 2, Richard Coico ⁎
Department of Microbiology and Immunology, City University of New York Medical School, New York, NY 10031, USA
Received 13 April 2006; returned to author for revision 5 July 2006; accepted 27 September 2006
Available online 22 November 2006Abstract
Ebola virus (EBOV) is known to cause a severe hemorrhagic fever resulting in high mortality. Although the precise host defense mechanism(s)
that afford protection against EBOV is not completely understood, T cell-mediated immune responses is believed to play a pivotal role in
controlling virus replication and EBOV infection. There have been no reports on mapping of MHC Class I-binding CTL epitopes for EBOV till to
date. In this study, we identified five HLA-A2-binding 9-mer peptides of EBOV nucleoprotein (NP) using computer-assisted algorithm. The
peptides were synthesized and examined for their ability to bind to MHC class I molecules using a flow cytometry based MHC stabilization assay.
Three of the EBOV-NP peptides tested (FLSFASLFL, RLMRTNFLI and KLTEAITAA) stabilized HLA-A2. The ability of the HLA-A2-binding
EBOV-NP peptides to generate peptide-specific CTLs was evaluated in HLA-A2.1 transgenic mice. Epitope-specific CTL responses were
confirmed by cytotoxic assays against peptide-pulsed target cells and interferon-γ ELISPOT assay. Each of the EBOV-NP peptides induced CTL
responses in HLA-A2-transgenic mice. Interestingly, all the three peptides were conserved in three different strains of Ebola (Zaire and Reston and
Sudan). Taken together, these findings provide direct evidence for the existence of EBOV-derived NP epitopes that may be useful in the
development of protective immunogens for this hemorrhagic virus.
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Ebola virus (EBOV) is a member of Filoviridae family of
viruses, which cause hemorrhagic disease in human and
nonhuman primates (Bray and Paragas, 2002). The filoviruses
are perhaps the least understood pathogenic viruses. They
emerge unpredictably in central Africa and cause epidemics of
severe hemorrhagic fever with high mortality rates (Sanchez et
al., 2001; Bray, 2002). The potential use of these viruses as
biowarfare agents is of significant concern (Bray and Paragas,
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doi:10.1016/j.virol.2006.09.042Coast and Reston (Sanchez et al., 1996). Infection with the
Ebola Reston virus can be fatal in monkeys but there are no
reported cases of lethal infections in humans. In contrast,
infections with Ebola Sudan or Ebola Zaire subtypes are often
fatal in humans (Bray and Paragas, 2002).
A significant pathogenic feature of EBOV infection is its
ability to severely impair the functional integrity of the immune
system. In EBOV-infected individuals, the failure of early
activation of T cells and the subsequent impaired humoral
responses are followed by extensive apoptosis of blood
leukocytes, phenomena that are closely associated with a fatal
outcome (Baize et al., 1999).
No effective therapies or vaccines are currently available for
filovirus infections. Results of earlier attempts to develop pro-
tective EBOV vaccines in guinea pigs and nonhuman primates
have been inconsistent (Lupton et al., 1980; Mikhailov et al.,
1994). Recent efforts have focused on the use of DNA vaccine
methods to stimulate T cell responses. Variable levels of protec-
tion were observed in mice and guinea pigs following EBOV
Fig. 1. Computational prediction of Ebola CTL epitopes by BIMAS algorithm.
The protein sequences of all six structural proteins of Ebola Zaire strain were
individually tested using BIMAS. The sequences were parsed into nine amino
acid peptides and the score of all the possible peptides were collected and then
grouped in to three different categories based on the scores.
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1997; Xu et al., 1998; Mellquist-Riemenschneider et al., 2003).
Although both the induction of humoral and cytotoxic T
lymphocyte (CTL) responses to Ebola nucleoprotein (NP) and
glycoprotein (GP) have been demonstrated in rodents, the
relative contribution of these responses to protection remains
unclear (Xu et al., 1998; Vanderzanden et al., 1998; Pushko et
al., 2000). Induction of CTL responses to an 8-mer GP sequence
was observed in mice immunized with irradiated EBOV or
irradiated liposome-encapsulated EBOV (Rao et al., 1999).
Wilson et al. (2001) demonstrated that the adoptive transfer of
NP-specific CTLs protected naive mice from lethal EBOV
challenge. However, passive transfer of polyclonal NP-specific
antiserum did not protect these mice. These results suggest that
cell-mediated effector mechanisms may play a more important
role in protection than humoral responses.
Despite the encouraging results of the these studies aimed at
developing candidate EBOV vaccines, none of the strategies
that protected mice or guinea pigs from lethal infection with this
virus have been shown to provide similar protection in
nonhuman primates (Geisbert et al., 2002). Recently, Sullivan
et al. (2003) reported the development of an accelerated vaccine
for Ebola. Single immunization with adenoviral (ADV) vectors
encoding the Ebola GP and NP was able to induce highly
effective protection against lethal challenge in nonhuman
primates. This correlated with the generation of Ebola-specific
CTL and antibody responses. Warfield et al. (2003) described
the production of virus-like particles (VLPs) of Ebola by
coexpressing GP and VP40 proteins. Mice vaccinated with
Ebola VLPs developed virus-specific antibodies including
neutralizing antibodies and these mice were 100% protected
against lethal challenge.
Numerous studies have been undertaken to more clearly
define the pathogenic mechanisms associated with EBOV
infection as well as the determinants of protective immunity
(Gupta et al., 2004). Despite these efforts, many questions
regarding the pathophysiology and host defense mechanisms
involved in EBOV infection remain unanswered. The paucity of
information related to the immunogenic T cell epitopes
expressed by EBOV limits the ability to examine in vivo T
cell responses. To date, knowledge of such EBOV epitopes has
been derived from studies in mice. While these investigations
provide insights into the genetic markers of EBOV that
stimulate murine effector T cell activation in the context of
specific MHC haplotypes, the information derived from such
studies may not be applicable to human MHC determinants. In
the present study, we used a combination of computational
prediction methods together with in vitro and in vivo assays to
identify three human HLA-A2.1-restricted CTL epitopes for the
nucleoprotein of EBOV.
Results
Computational prediction of EBOV-NP CTL epitopes
The total protein sequences of six structural EBOV proteins
(NP, GP, VP24, VP30, VP35 and VP40) were parsed intopeptides of nine amino acids in length, each overlapping by
eight amino acids as described in Materials and methods. The
HLA-A2.1-specific BIMAS algorithm-scoring pattern of the
peptides is depicted in Fig. 1. Most of the peptides scored very
low (<1) as shown. Thirty-two peptides with scores >50 were
identified as predicted binders. Among these, twelve were
components of EBOVNP. The highest ranking predicted EBOV
NP epitopes, as determined by BIMAS analysis, are presented in
Table 1. Based on these ranking scores, five NP peptides with
scores >150 were selected for further study.
Evaluation of synthetic peptides as candidate CTL epitopes
Synthetic peptides identified as candidate EBOVepitopes in
the context of HLA-A2.1 were evaluated for MHC class I
binding using MHC stabilization assay. Three out of the five
selected EBOV NP-derived peptides (FLS, RLM and KLT)
stabilized the expression of HLA-A2.1 on T2 cells as evidenced
by increased MFI profiles when compared with the no peptide
control (Fig. 2). An increase in MFI values >200% was noted
with the FLS and KLT peptides. This increase was similar to that
observed using the positive control peptide (GIL). The RLM
peptide caused a 90% increase in MFI over no peptide control as
shown in Fig. 2. The other two EBOV NP peptides, AMN and
YQG, induced 13% and 9% increases in MFI, respectively.
Thus, based on our selection criterion for the identification of
peptides as high binders, the peptide nanomers FLS and KLT
were classified as strong binders, the peptide RLM as moderate
binder and AMN and YQG as nonbinders. Nonbinder peptides
were excluded for further analysis. The three predicted binders,
FLS, KLT and RLM, were used to assess their ability to induce
CTL responses in vivo.
Immunogenicity of EBOV-NP peptides in vivo
In order to gain insight into the functional properties of the
high-binding peptides, the three selected EBOV NP peptides
Fig. 3. Enumeration of IFN-γ producing cells by ELISPOT. The IFN-γ
ELISPOT assay was performed as described in Materials and methods. EBOV
NP-derived peptides tested included: FLS, RLM and KLT (abbreviations for
nanomer peptides are given in the legend of Fig. 2). Peptide-specific ELISPOTs
reflect total number of spots minus backgrounds observed in the absence of
peptide. The experiment was performed at least three times and the results
shown represent mean IFN-γ ELISPOTS/106±SD from a representative
experiment.
Table 1
Predicted CTL epitopes for Ebola nucleoprotein (NP)a
a Peptides noted in black indicate EBOV NP motifs with BIMAS scores
>50. Those with green letters indicate motifs with BIMAS scores >150
which were selected for in vitro study. These were abbreviated throughout
the text using the first three letters of the amino acids in a given peptide
(YQG, FLS, RLM, KLT, AMN). Red-lettered amino acids designate
position-disparate NP residues among the three strains analyzed.
b Ebola strains analyzed included Ebola Zaire (EBOV_Z), Ebola Reston
(EBOV_R) and Ebola Sudan (EBOV_S).
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A2.1 transgenic mice. Animals were immunized with peptides
as described in Materials and methods. Immune responses were
assessed using functional assays including, IFN-γ ELISPOT
and CTL assay.
Peptide-specific T cells were enumerated by measuring IFN-
γ-producing cells by ELISPOT assay. As shown in Fig. 3, a
substantial number of T cells harvested from mice immunizedFig. 2. Evaluation of Peptide binding to HLA-A2 as assessed by MHC class I
stabilization. The ability of peptides to stabilize HLA-A2 on the surface of T2
cells was assessed by flow cytometric analysis after staining peptide-treated
cells with anti-HLA-A.2 antibody. Five high scoring EBOV-NP peptides,
FLSFASLFL (FLS), AMNEENRFV (AMN), YQGDYKLFL (YQG),
RLMRTNFLI (RLM) and KLTEAITAA (KLT), were evaluated for binding
to HLA-A2. A known binder, GILGFVFTL, and a nonbinding peptide,
IAGNSAYEY, were used as positive and negative controls respectively. Each
peptide was used at 50 μM concentration.with the selected EBOV NP peptides responded by producing
IFN-γ. The responses observed indicated a dose-dependent
relationship between the concentration of peptide used for
stimulation and the number of IFN-γ-producing T cells (Fig. 3).
Two of the EBOV NP peptides, RLM and KLT, were found to
generate strong peptide-specific T cell responses by virtue of
their ability to induce increased frequencies of IFN-γ-producing
T cells as compared to the other high-binding peptide, FLS. The
frequency of IFN-γ-producing cells in the RLM- and KLT-
primed splenocyte population was found to be 535 and 338 per
one million cells, respectively, when cells were stimulated with
100 μM peptide (Fig. 3). In contrast, the frequency of IFN-γ-
producing cells generated in response to FLS at the 100-μM
peptide concentration was found to be 155/106 cells. This
response decreased with decreasing peptide concentrations
showing a dose-dependent profile.
Splenocytes from peptide-primed HLA-A2.1 transgenic
mice were tested for their cytolytic activity by measuring their
ability to serve as effector cells that kill peptide-pulsed T2
target cells expressing HLA-A2.1. As shown in Fig. 4,
effector cells generated after 5 days of culture with specific
peptides killed peptide-pulsed target cells in a dose-dependent
manner. Cells stimulated with the RLM peptide exhibited the
highest level of specific lysis (42.41%) at an E:T ratio of
40:1. This was followed by the KLT and FLS peptides,
showing specific lysis of 34.51% and 19.87%, respectively, at
the 40:1 E:T ratio (Fig. 4).
Discussion
Cellular and humoral immunity each play pivotal roles in
host defenses against viral pathogens. Previous studies aimed at
elucidating immune mechanisms associated with protective
Fig. 4. Immunizations with Ebola peptides elicit in vivo CTL responses in HLA-
A2.1 transgenic mice. Mice were immunized with EBOV NP peptides FLS,
RLM and KLT (abbreviations for nanomer peptides are given in the legend of
Fig. 2). After 10 days, splenocytes were harvested and pooled splenocytes were
restimulated for 5 days with the corresponding peptides (n=3 per peptide
tested). Immune effector cells were incubated with target cells at the effector:
target ratios shown. CTL assays were performed following a 4-h incubation
period. Data points represent mean percent-specific lysis±SD as measured by
quantitation of LDH release. Results from a representative experiment among
three performed are shown.
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the cellular arm of the immune system. Protective humoral
responses to EBOV have also been demonstrated and shown to
result from B cell responses to EBOV GP (Jahrling et al.,
1996). In contrast, both EBOV GP and NP are known to induce
T cell responses (Sullivan et al., 2000; Xu et al., 1998). A
greater understanding of the nature of protective immune
responses is necessary to facilitate the development of future
vaccines against this virus. To date, there have been no reports
showing CTL responses induced by EBOV-derived peptides
specific for human class I alleles. The present study was
undertaken to identify candidate CTL epitopes present in the
NP of EBOV. Synthetic EBOV NP peptides with computa-
tionally predicted class I-binding motifs were studied for their
ability to up-regulate and stabilize HLA-A2.1 molecules
expressed by T2 cells.
Computational methods combined with in vitro/in vivo
studies have proven to be very useful in the identification of
immunogenic T cell epitopes from defined antigens and
pathogens (Huang et al., 2004, Turcanova and Hollsberg,
2004; Boesen et al., 2005; Simmons et al., 2004). Many groups
have demonstrated the utility of the matrix-based algorithms
such as BIMAS and SYFPEITHI in predicting viral and tumor
antigen-specific CTL epitopes (Huang et al., 2004; Lu and
Celis, 2000; Sun et al., 2000; Turcanova and Hollsberg, 2004;
Vonderheide et al., 1999). Using the matrix-based algorithm,
BIMAS, we were able to predict five MHC class I-binding NP
peptides within the structural proteins of EBOV (Table 1).
To validate the ability of these predicted epitopes to ligate
HLA-A2.1, we used a quantitative flow cytometric assay to
measure surface induction of class I molecules on TAP-deficient
cells. This commonly used method measures the relative
binding affinity of different peptides to the same class I allele
(Pamer and Cresswell, 1998). Three of the five selected EBOVNP-derived peptides (FLS, RLM and KLT) stabilized the
expression of HLA-A2 molecules expressed on T2 cells. T2
cells treated with the other two NP-derived peptides (AMN and
YQG) did not show any appreciable class I stabilization. Each
of the EBOV peptides capable of binding HLA-A2 on T2 cells
contains a primary anchor residue at the 2nd position (L). In the
case of nonbinding peptide AMN, the presence of other HLA-
A2 anchoring residues, namely, M at the 2nd position and V at
the 9th position, did not correlate with any appreciable HLA-A2
stabilization. Therefore, despite the presence of anchor residues
known to correlate with HLA-A2 binding, AMN failed to bind
to this class I allele. It has been shown that the success rate of
computational algorithms in predicting MHC class I binding
can range from 30% to 70% depending on the class I allele and
peptide motif under study (Feltkamp et al., 1994; Sette et al.,
1994). Other factors that contribute to the success or failure of
these prediction algorithms to map MHC class I-binding
epitopes include peptide length, spacing between required
anchoring residues, and the presence of other amino acids which
may act as secondary anchor residues (Eberl et al., 1993;
Ruppert et al., 1993; Zhou et al., 1992). Combinations of these
factors may also influence the ability of peptides to bind MHC
class I molecules. Thus, it is difficult to accurately explain the
failure of some of the EBOV peptides identified computation-
ally as candidate epitopes to stabilize HLA-A2.1 molecules.
Peptide-induced stabilization of MHC class I molecules is
directly correlated with their ability to induce CTL response in
vivo (Sette et al., 1994). We therefore tested the ability of HLA-
A2.1-binding EBOV peptides FLS, RLM and KLT to stimulate
CTL responses in HLA-A2.1 transgenic mice. The moderate-
binding peptide RLM was found to induce the strongest CTL
responses as compared with the high-binding peptides tested
(FLS and KLT). RLMwas also markedly more efficient than the
high-binding peptides in its ability to induce peptide-specific
IFN-γ-secreting cells.
Identification of EBOV epitopes that induce CTL responses
in humans previously infected with EBOV will advance our
ability to develop vaccine strategies for this pathogen. Gupta et
al. (2004) have demonstrated the critical importance of CD8+ T
cells in virus clearance. Relatively few studies have addressed
the subject of EBOV CTL epitopes focusing on the identifica-
tion of murine T cell epitopes. Rao et al. (1999) reported the
identification of a murine EBOV GP CTL epitope. Studies by
Warfield et. al. (2003, 2005) using lipid-encapsulated particles
containing EBOV GP and matrix viral protein (VP40) have
shown that this approach is a highly efficacious method of
immunization against EBOV infection. Other studies have used
EBOV subunit vaccines to identify the major EBOV determi-
nants capable of conferring immune protection against this
pathogen in mice and guinea pigs (Wilson et al., 2001; Olinger
et al., 2005). A recent study attempted to map murine CTL
epitopes of EBOV-NP using overlapping peptides (Simmons et
al., 2004). They identified three EBOV-NP epitopes specific for
H-2d- as well as H-2b-restricted class I molecules.
Knowledge of the immunogenic motifs that induce EBOV-
specific CTL responses will facilitate the development of
effective vaccination strategies. Our approach to mapping and
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motifs has confirmed the existence of three epitopes capable of
generating peptide-specific CTL responses. To our knowledge,
this is the first report describing such EBOV epitopes. Future
studies using nonhuman primates to examine these candidate
immunogenic epitopes should be undertaken to confirm their
ability to stimulate EBOV-specific CTLs capable of protecting
animals from challenge with live virus. In addition, studies to
explore the utility of these mapped EBOVepitopes as diagnostic
tools in monitoring and assessing T cell responses following
infection or vaccination will also be useful.
Materials and methods
Computational prediction of candidate CTL epitopes for Ebola
A well-known matrix-based prediction algorithm, BIMAS
(http://bimas.dcrt.nih.gov/molbio/hla_bind/), was used for
the prediction of EBOV peptides binding to HLA-A2.1
(Parker et al., 1994). The amino acid sequences of six
structural proteins of Ebola Zaire strain (NCBI accession
no. NC_002549) were individually tested using these
algorithms. The total sequences of each of this protein
were parsed into peptides of nine amino acids in length,
each overlapping by eight amino acids. The selected
peptides were then screened for similarity to the human
genome using the NIH Blast server (http://www.ncbi.nlm.
nih.gov/blast/). Peptides showing homology with regard to
the human proteome were eliminated for further study.
Cell lines and peptides
TAP-deficient T2 cells expressing HLA-A2 were obtained
from American Type Culture Collection (Manassas, VA) and
maintained in IMDM (Invitrogen, Grand Island, NY) supple-
mented with 20% fetal bovine serum (FBS) (Atlanta
Biologicals, Lawrenceville, GA) at 37 °C with 5% CO2. All
peptides used in this study were synthesized commercially
(Sigma-Genosys, Woodlands, TX) and documented to be
>95% pure. Peptides were dissolved either in water or DMSO
and diluted to desired concentrations in phosphate buffered
saline (PBS).
Mice
Six- to eight-week-old C57BL/6J transgenic mice expressing
HLA-A2.1 [C57BL/6-TgN (HLA-A2.1) 1Enge] were obtained
from The Jackson Laboratory (Bar Harbor, ME). Mice were
maintained in our animal facility under specific pathogen-free
conditions.
MHC stabilization assay
The ability of peptides to bind to HLA-A2.1 molecules was
evaluated using an MHC class I stabilization assay (Nijman et
al., 1993). Briefly, T2 cells were grown overnight at 37 °C in
IMDM supplemented with 20% FBS. Cells were harvested andwashed twice with serum-free AIM-V medium (Invitrogen) and
then incubated (5 x105/250 μl) with 50 μM of individual
peptides at 37 °C for 18 h in AIM-V medium. Following
incubation, cells were washed twice with staining buffer (PBS
containing 3% FBS) and stained for 30 min at 4 °C with the
FITC-conjugated anti-HLA-A2.1 antibody (Pharmingen, San
Diego, CA) at a concentration of 500 ng per reaction in 100 μl
of staining buffer. Stained cells were washed twice with staining
buffer and resuspended in PBS. HLA-A2.1 expression was
measured flow cytometrically using a BD LSRII flow cytometer
(BD Biosciences, Mountain View, CA) and the data analyzed
using FlowJo software (Tree Star, Ashland, OR). A synthetic
EBOV peptide capable of causing a >150% increase in MFI
values over the ‘no peptide’ control was considered as a “high
binder”. The peptide GILGFVFTL, a well-known HLA-A2.1
epitope derived from influenza matrix antigen, was used as a
positive control (Micheletti et al., 2002). The peptide IAGN-
SAYEY, a known HLA-A2.1 nonbinder, was used as a negative
control (Bhasin et al., 2003).
Generation of CTLs in HLA-A2.1 transgenic mice
Eight-week-old HLA-A2.1 transgenic female mice were
immunized with 100 μg of individual EBOV test peptides
together with 140 μg of an HBV-derived helper epitope (128-
140AA). The peptides were emulsified in SEPPIC adjuvant-
Montanide ISA 70 (Seppic, France) at a ratio of 1:1 and injected
subcutaneously. Mice were boosted once a week following
initial immunization and the splenocytes were harvested one
week after boosting to assess CTL responses.
Stimulation of CTL effector cells in vitro
Single-cell suspensions were prepared from splenocytes of
immunized mice. RBCs were lysed using ACK lysis buffer
and the cells were used immediately for ELISPOT assay.
Alternatively, cells were cultured for 5 days in RPMI
medium supplemented with 10% FBS, 10 mM HEPES and
50 μM 2-mercaptoethanol, 10% T-stim (Pharmingen) and
10 μM of EBOV peptides. Nonadherent CTLs were
harvested at the end of the culture period and used as
effector cells in the CTL assay described below.
ELISPOT assay
Peptide-specific T cells were enumerated using ELISPOT
assays (Lycke and Coico, 1996). ELISPOT plates (Pharmingen)
were coated overnight at 4 °C with 5 μg/ml of monoclonal anti-
mouse IFN-γ antibody. After blocking the wells for 2 h with
RPMI medium supplemented with 10% FBS, 100 μl of cell
suspension (2×106/ml) with different peptide concentrations
(0.01 μM–100 μM) were added to each well. A positive control
(5 μg/ml, Con A) and a ‘no peptide’ negative control were
included in all assays. The plates were incubated overnight at
37 °C in a 5% CO2 humidified incubator. Following incubation,
the wells were washed twice with deionized water and three
times with wash buffer (PBS+0.05% Tween-20). Biotinylated
262 K. Sundar et al. / Virology 360 (2007) 257–263anti-mouse IFN-γ was added to each well at a concentration of
2 μg/ml and the plates were incubated for 2 h at room
temperature. Following three washes, Streptavidin–HRP was
added to each well and the plates were incubated for 1 h at room
temperature. The plates were washed three times and colori-
metric reactions developed using 3-amino 9-ethylcarbazole
(AEC) substrate. ELISPOTs were enumerated using a dissecting
microscope and values are expressed after subtracting the
background.
CTL assay
CTL responses were measured using a nonradioactive CTL
assay that quantitates lactate dehydrogenase (LDH) released by
target cells (Promega, Madison, WI). T2 cells were used as
target cells and were pulsed overnight with individual test
peptides (10 μM). Peptide-stimulated effector cells from
immunized mice were incubated with these peptide-loaded
T2 target cells at different effector: target cell ratios ranging
from 40:1 to 5:1 in a 96-well U-bottom plate for 4 h at 37 °C.
Fifty microliters of culture supernatants was then harvested
from each well and tested for LDH activity using a
chromogenic substrate. Absorbance was measured at 495 nm
using an ELISA reader (Bio-Rad, Hercules, CA). The percent-
specific cell lysis was calculated using the following formula:
100× [(experimental−effector spontaneous)− target sponta-
neous] / [target maximum− target spontaneous].
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